modelRucaparib

Diagram of Rucaparib

Extends from Pharmacolibrary.Drugs.ATC.L.L01XK03.

Information

name:Rucaparib
ATC code:L01XK03
route:oral
compartments:2
dosage:600mg
volume of distribution:113L
clearance:15.3L/h
other parameters in model implementation

Rucaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of certain types of ovarian and prostate cancer. It is used especially in patients with BRCA mutations or deficiencies in homologous recombination repair. Rucaparib is currently approved and in clinical use.

Pharmacokinetics

Pharmacokinetic parameters reported in adults (cancer patients), following multiple oral doses of 600 mg twice daily.

References

  1. Green, ML, et al., & Xiao, JJ (2022). Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors. Cancer chemotherapy and pharmacology 89(5) 671–682. DOI:10.1007/s00280-022-04413-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35397664

  2. Liao, M, et al., & Xiao, JJ (2022). Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib. Clinical pharmacokinetics 61(11) 1477–1493. DOI:10.1007/s40262-022-01157-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36107395

  3. Konecny, GE, et al., & Xiao, JJ (2021). Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Gynecologic oncology 161(3) 668–675. DOI:10.1016/j.ygyno.2021.03.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33752918

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)